| Full Name | One Health-ashland |
|---|---|
| Speciality | Clinic/Center |
| Location | 501 Main Street, Ashland, Montana |
| Authorized Official Name and Position | David Mark (CEO) |
| Authorized Official Contact | 4066654103 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| One Health-ashland 10 4th St W Hardin MT 59034-1802 Ph: (406) 665-4103 | One Health-ashland 501 Main Street Ashland MT 59003 Ph: (406) 784-2346 |
| NPI Number | 1932575149 |
|---|---|
| Provider Enumeration Date | 08/12/2015 |
| Last Update Date | 06/24/2022 |
| Medicare PECOS PAC ID | 8820246077 |
|---|---|
| Medicare Enrollment ID | O20160405001707 |
News Archive
A study published online on February 1 in the Journal of Experimental Medicine (www.jem.org) shows that antiviral proteins called type I interferons (IFNs) are needed to fend off infection with an exotic mosquito-borne virus called Chikungunya virus.
A combination of drugs widely used to treat infections caused by HIV appears to stop brain damage caused by the virus as well, according to a study published in the October 9, 2007, issue of Neurology, the medical journal of the American Academy of Neurology.
Protalix Biotherapeutics, Inc. (NYSE-Amex: PLX), announced the completion of its pivotal Phase III trial for prGCD, the Company's proprietary plant-cell expressed recombinant form of glucocerebrosidase (GCD) for the treatment of Gaucher disease. The trial enrolled a total of 31 patients across Europe, North America, South America, Israel and South Africa. No serious adverse events were reported in this trial.
A new study pinpoints the genetic changes that enable Tibetans to thrive at altitudes where others get sick.
› Verified 6 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932575149 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QF0400X | Clinic/center - Federally Qualified Health Center (fqhc) | (* (Not Available)) | Primary |
News Archive
A study published online on February 1 in the Journal of Experimental Medicine (www.jem.org) shows that antiviral proteins called type I interferons (IFNs) are needed to fend off infection with an exotic mosquito-borne virus called Chikungunya virus.
A combination of drugs widely used to treat infections caused by HIV appears to stop brain damage caused by the virus as well, according to a study published in the October 9, 2007, issue of Neurology, the medical journal of the American Academy of Neurology.
Protalix Biotherapeutics, Inc. (NYSE-Amex: PLX), announced the completion of its pivotal Phase III trial for prGCD, the Company's proprietary plant-cell expressed recombinant form of glucocerebrosidase (GCD) for the treatment of Gaucher disease. The trial enrolled a total of 31 patients across Europe, North America, South America, Israel and South Africa. No serious adverse events were reported in this trial.
A new study pinpoints the genetic changes that enable Tibetans to thrive at altitudes where others get sick.
› Verified 6 days ago
Ashland Community Health Center Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 501 Main St., Ashland, MT 59003 Phone: 406-784-2346 Fax: 406-784-2711 |